Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. Harnessing the immune system to achieve deep and durable clinical responses in cancer. Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. We provide a professional and challenging work environment . Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. This is the Immunomic Therapeutics company profile. Active, Closed, Last funding round type (e.g. Operating Status Active. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. Innovative Cellular Therapeutics (ICT) | LinkedIn CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000 Coordinates: 245831.9N 1213154.0E. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. ITI-1000 GBM - Cell Therapy. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. Immunomic Therapeutics to Present at Biotech Showcase 2023 Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. Report this profile . ITI-2000 HPV+ Tumors. Edit Lists Featuring This Company Section, Immunomic Therapeutics to Present at Biotech Showcase 2023. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. Companies. On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. What is health insurance like at Immunomic Therapeutics. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. DC Inno - Exclusive: Rockville biotech expanding, 'on the prowl' for Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. Company Type For Profit. HLB also secured an option to make further investment into the company in the months ahead. Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Hershey, PA & Rockville, MD and Tokyo, Japan. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. Immunomic Therapeutics General Information. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Our Pipeline | Xilio Therapeutics Animal Health All. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571 ITI Company: Checkmate-548 was the most recent hope for Opdivo in glioblastoma following the failures, in 2017 and 2019 respectively, of Checkmate-143 in the second-line setting and Checkmate-498 in first-line. Immunomic Therapeutics, Inc. | LinkedIn Contact Email info@immunomet.com. Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). Pay, Holidays and PTO appear to be very good. Vaccine technology developed at Johns Hopkins could lead to - Hub Immunomic Therapeutics Stock Price, Funding, Valuation, Revenue Description. Frans broad experience and deep knowledge in regulatory affairs will be a tremendous asset during a critical time for ITI, as we continue our interactions with the FDA and other key regulatory agencies regarding our clinical programs, stated William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Juniper Point ImmunoMet Therapeutics - Crunchbase Company Profile & Funding This is the Immunomic Therapeutics company profile. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Immunomic, Colmmune partner on cancer immunotherapy - ScienceBoard.net 301-968-3501, ITI Media: Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. For more information, please visit www.immunomix.com. We are pleased to welcome HLB as a significant shareholder of Immunomic Therapeutics and look forward to working with them within the framework of the HLB Bio family of companies. Request a free trial. William Hearl - President & CEO - Immunomic Therapeutics, Inc ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics, Inc. may be just for you. ITI-1001 is an alternative, cell-free approach to treating GBM. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. 2003 Sep 26;278(39):37926-36. Team - Immunomic Therapeutics Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Jan 2006 - Present17 years 2 months. ITI-2000 HPV+ Tumors.
Former Wspa Reporters,
Explain How A Brake Fluid Tester Operates,
Harry Potter Casting Call 2021,
Alyssa Bustamante Married,
Presentation High School San Francisco,
Articles I